Ethos’ Investment & the Creation of Vertice MedTech Group
Amayeza Abantu Biomedical (Pty) Ltd, Amayeza Abantu meaning medicine for the people in isiXhosa, one of South Africa’s indigenous languages, was established in 1998. A material milestone for the company was the conclusion of agreements in 2001 with St. Jude Medical for the marketing and distribution of its Cardiac diagnosis and Cardiac Rhythm Management product range in South Africa. In 2016 Abbott Laboratories (www.abbott.com) acquired St Jude Medical.
Over the years the company has developed substantially, diversifying its activities in wound care, neuromodulation and spine surgery while extending its footprint across the Sub-Saharan region. This has resulted in the Amayeza Abantu becoming a leading provider of quality solutions throughout the continent. Today, Amayeza Abantu is renowned for its ability to deliver specialist, quality, state-of-the-art medical technology and skills transfer. The strong relationships that developed over 20 years and continue with key healthcare professionals and hospitals in our region, laid the foundation to partner with Ethos.
Ethos is an investment firm, managing investments in private equity and credit strategies in South Africa and selectively in sub-Saharan Africa.
It was instrumental in establishing the private equity asset class in the sub-Saharan region, concluding the: first buyout (1984); first public-to-private deal (1992); first BEE deal (1994); and, first international fund raising (1996). They are currently investing Ethos Fund VI, with R8.6 billion of committed capital and have assets under management of over R11 billion.
It is in this Fund VI that Ethos acquired a majority stake in Amayeza and Legacy, resulting in a new entity Vertice MedTech Group (VMTG), and its first vertical business is Vertice Health Care (VHC).
Ethos distinguishes itself in the South African market by combining financial discipline with value-enhancing strategies, in partnership with portfolio company management teams. Their deep experience coupled with a partnership approach is why we believe them to be the right shareholders and partners for our business into the future.
Haemotec (Pty) Ltd was established in 2001 as a distributor of specialised products used in the field of transfusion medicine.
Our portfolio has since grown to encompasses a wider range of products, that not only cover blood transfusion, but also in-vitro diagnostics, tissue banking, hospital and surgical.
Through our products we are involved in the collection, processing, testing, storage, infusion and management of blood and human tissue.
We are proud to be associated with some of the leading manufactures in our market sector.
The cornerstone of our success has always been our customer orientated approach while providing quality, state-of-the-art technology.
Our company headquarters is located in Meadowdale, Johannesburg and our business reach extends to most Southern African countries as well as Ghana and Nigeria.